These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

730 related articles for article (PubMed ID: 8177717)

  • 61. Distribution of a bovine spongiform encephalopathy-derived agent over ion-exchange chromatography used in the preparation of concentrates of fibrinogen and factor VIII.
    Foster PR; Griffin BD; Bienek C; McIntosh RV; MacGregor IR; Somerville RA; Steele PJ; Reichl HE
    Vox Sang; 2004 Feb; 86(2):92-9. PubMed ID: 15023177
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Side effects of substitution therapy.
    Aledort LM
    Scand J Haematol Suppl; 1984; 40():331-3. PubMed ID: 6433459
    [No Abstract]   [Full Text] [Related]  

  • 63. Danazol increases factor VIII and factor IX in classic hemophilia and Christmas disease.
    Gralnick HR; Rick ME
    N Engl J Med; 1983 Jun; 308(23):1393-5. PubMed ID: 6405274
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Treatment of hemophilia].
    Stavem P; Hjort PF
    Tidsskr Nor Laegeforen; 1970 Jul; 90(13):1413-8. PubMed ID: 5453192
    [No Abstract]   [Full Text] [Related]  

  • 65. Evidence-based use of recombinant FVIIa (NovoSeven, NiaStase) for the treatment of hemophilia with inhibitors in children and adolescents.
    Goldstein B; Geldziler B; Bjerre J; Seremetis S
    Transfus Apher Sci; 2008 Feb; 38(1):25-32. PubMed ID: 18267372
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Blood protein technological industrial developments as a mirror of fundamental studies bgy the Institute of Biochemistry of the Ukrainian National Academy of Sciences].
    Volkov GL; Andrianov SI; Horoshnykova TV; Borysevych OS; Gavryliuk OS
    Ukr Biokhim Zh (1999); 2000; 72(4-5):109-21. PubMed ID: 11200439
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Viral hepatitis in hemophiliac patients treated with commercial concentrates of factors VIII and IX].
    Miranda ML; Lissen E; Vinuesa M; Jiménez JM; García de Pesquera F; Leal M
    Med Clin (Barc); 1985 Apr; 84(13):516-9. PubMed ID: 3923278
    [No Abstract]   [Full Text] [Related]  

  • 68. [Prophylactic treatment with clotting factor to prevent joint damage in patients with severe haemophilia: costs versus benefits].
    Roosendaal G; Lafeber FP
    Ned Tijdschr Geneeskd; 2007 Nov; 151(47):2606-8. PubMed ID: 18161260
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Review of the hepatitis A epidemics in hemophiliacs in Europe.
    Vermylen J; Peerlinck K
    Vox Sang; 1994; 67 Suppl 4():8-11; discussion 24-6. PubMed ID: 7831867
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Preparation and clinical use of a new factor IX concentrate].
    Lopaciuk S; Poszwiński P
    Acta Haematol Pol; 1978; 9(2):107-12. PubMed ID: 665130
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Immune tolerance induction and the treatment of hemophilia. Malmö protocol update.
    Berntorp E; Astermark J; Carlborg E
    Haematologica; 2000 Oct; 85(10 Suppl):48-50; discussion 50-1. PubMed ID: 11187871
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [Current status of viral safety of virus inactivated factor VIII and IX concentrates in treatment of hemophilia].
    Pollmann H
    Infusionsther Transfusionsmed; 1994 Aug; 21 Suppl 1():80-3. PubMed ID: 8000261
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Medical staff conference: Hemophilia and von Willebrand's disease. Fourth annual Paul M. Aggeler memorial lecture.
    West J Med; 1974 Mar; 120(3):226-32. PubMed ID: 4544608
    [No Abstract]   [Full Text] [Related]  

  • 74. Importance of pharmacokinetics in the management of hemophilia.
    Barnes C
    Pediatr Blood Cancer; 2013; 60 Suppl 1():S27-9. PubMed ID: 23109436
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation.
    Hay CR; Brown S; Collins PW; Keeling DM; Liesner R
    Br J Haematol; 2006 Jun; 133(6):591-605. PubMed ID: 16704433
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Transmission of human parvovirus B19 by plasma derived factor VIII concentrates.
    Laurian Y; Dussaix E; Parquet A; Chalvon-Demersay A; d'Oiron R; Tchernia G
    Nouv Rev Fr Hematol (1978); 1994 Dec; 36(6):449-53. PubMed ID: 7753615
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Biochemical characterization of recombinant factor IX.
    Bond M; Jankowski M; Patel H; Karnik S; Strang A; Xu B; Rouse J; Koza S; Letwin B; Steckert J; Amphlett G; Scoble H
    Semin Hematol; 1998 Apr; 35(2 Suppl 2):11-7. PubMed ID: 9565161
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Long-term low-dose secondary prophylaxis for severe and moderate hemophilia children with arthropathy in China: a single-center observation study].
    Wu RH; Wu XY; Zhang NN; Zhao L; Zhang JS; Zhen YZ; Peng Y
    Zhonghua Xue Ye Xue Za Zhi; 2013 Jul; 34(7):632-4. PubMed ID: 23906463
    [No Abstract]   [Full Text] [Related]  

  • 79. Current issues in prophylactic therapy for persons with hemophilia.
    Dunn AL; Abshire TC
    Acta Haematol; 2006; 115(3-4):162-71. PubMed ID: 16549891
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Occurrence of inhibitors in previously untreated or minimally treated patients with haemophilia A after exposure to a plasma-derived solvent-detergent factor VIII concentrate.
    Gringeri A; Monzini M; Tagariello G; Scaraggi FA; Mannucci PM;
    Haemophilia; 2006 Mar; 12(2):128-32. PubMed ID: 16476086
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 37.